Ascendis Pharma A/S vs Sony Group Corp — how do they compare? Ascendis Pharma A/S trades at $254.5 (market cap $16.67B), while Sony Group Corp trades at $23.69 (market cap $138.43B). The key difference: Sony Group Corp is far larger — about 8.3× Ascendis Pharma A/S's market cap, and Sony Group Corp pays a 0.67% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | SONY | |
|---|---|---|
Market Cap | $16.67B | $138.43B |
Sector | Health | Technology |
52-Week High | $277.18 | $30.26 |
52-Week Low | $189.74 | $19.32 |
Enterprise Value | $17.04B | $136.35B |
Dividend Yield | — | 0.67% |
Trailing returns across standard periods
Latest headlines on both assets
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →Sony Group is a conglomerate with consumer electronics roots, which not only designs, develops, produces, and sells electronic equipment and devices, but also is engaged in content businesses, such as console and mobile games, music, and movies. Sony is a global top company of CMOS image sensors, game consoles, professional broadcasting cameras, and music publishing, and is one of the top players on digital cameras, wireless earphones, recorded music, movies, and so on. Sony's business portfolio is well diversified with six major business segments. The company fully consolidated Sony Financial in September 2020, which provides life and non-life insurance, banking, and other financial services.
Read more on SONY →